Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI heart scans could replace MRI for chemo patients

NCT ID NCT07093918

Diagnosis Sponsor: The Royal Wolverhampton Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether AI-enhanced 3D and 2D echocardiography (heart ultrasound) can detect chemotherapy-related heart damage as accurately as cardiac MRI. Researchers will compare these new imaging methods with standard ultrasound and MRI in 120 adults who have received potentially heart-damaging chemotherapy. If the AI methods prove reliable, they could offer a faster, cheaper, and more accessible way to monitor heart health during cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
V-echo and L-echo (AI-enhanced 3D and 2D echocardiography imaging systems)
What this could lead to
If successful, this could provide a quicker, more accessible way to monitor heart health in chemotherapy patients, reducing the need for costly MRI scans.
What could go wrong
This is an early-stage diagnostic study with only 120 participants. The AI methods may not prove accurate enough to replace MRI, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be identified after referral by the oncology team for routine echocardiography surveillance following the prescription of potentially cardiotoxic chemotherapy

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Received potentially cardiotoxic chemotherapy * Participant requires echocardiography surveillance as standard current practice Exclusion Criteria: * Below the age of 18 years old * Inability to give informed consent * Implanted cardiac devices * Not having received cardiotoxic chemotherapy. Ineligible patients and patients not wishing to take part will be excluded, the reasons for this will be recorded and baseline CONSORT demographics noted including age, gender, ethnicity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiotoxicity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.